The Necessity of Bile Cultures in Patients With Acute Cholangitis
1 other identifier
interventional
440
1 country
1
Brief Summary
Acute cholangitis with obstructive jaundice is a condition which needs biliary drainage and appropriate antibiotics. Bile culture is an optional laboratory test according to 2013, 2018 Tokyo guideline, but the clinical significance is yet unproven. And its results might indicate less information of the true pathogen regarding normal flora. Previous study conducted at our institute found drug-resistant pathogens identified in bile culture had no impact on the outcome. So the investigators are conducting a multicenter randomized controlled trial comparing groups which considers both blood and bile culture as control and which considers only blood culture as trial group in order to prove bile culture provides no additional helpful clinical information.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Aug 2015
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 27, 2015
CompletedStudy Start
First participant enrolled
August 27, 2015
CompletedFirst Posted
Study publicly available on registry
November 10, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 20, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 30, 2024
CompletedMay 30, 2024
May 1, 2024
8.6 years
August 27, 2015
May 23, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Organ Failure
Shock, AKI, altered mentality, Acute respiratory distress
during hospitalization and empirical antibiotic administration. (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months)
Secondary Outcomes (3)
Hospital days
through study completion, an average of 1 month
Re-intervention for biliary drainage
through study completion, an average of 1 month
Mortality
through study completion, an average of 1 month
Study Arms (2)
Antibiotics change is based on both blood and bile cultures
NO INTERVENTIONEmpirical antibiotic therapy was initially conducted for patients. In the control group, the initial antibiotic regimen was maintained if both blood and bile cultures were negative or if all identified organisms were sensitive to empirical treatment. However, the empirical antibiotics were switched to appropriate antibiotics considering the results from blood and bile cultures if any organism demonstrated resistance. Following antibiotic modification in the experimental and control groups, additional biliary drainage procedures (ERCP or PTBD) were performed for considering ineffective drainage on the discretion of physicians.
Antibiotics change is based only on the blood culture
EXPERIMENTALEmpirical antibiotic therapy was initially conducted for patients. In experimental group, the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group. Following antibiotic modification in the experimental and control groups, additional biliary drainage procedures (ERCP or PTBD) were performed for considering ineffective drainage on the discretion of physicians.
Interventions
the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group
Eligibility Criteria
You may qualify if:
- (1) patients aged ≥20 years with suspected or confirmed acute cholangitis according to the 2013 and 2018 Tokyo guidelines
You may not qualify if:
- inability to provide informed consent
- no evidence of acute cholangitis diagnostics as per the guidelines
- development of organ failure before random allocation or organ failure by non-cholangitis causes
- undergoing bile culture tests after the onset of organ failure
- failure to have bile or blood culture tests
- patients who were already administered antibiotics for other conditions
- unsuccessful PTBD insertion
- failure to achieve complete bile drainage via PTBD
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Seoul National University Hospital
Seoul, 110-744, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sang Hyub Lee, MD. PhD.
Department of internal medicine and liver research institute, Seoul national university hospital, Seoul, Korea
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
August 27, 2015
First Posted
November 10, 2015
Study Start
August 27, 2015
Primary Completion
March 20, 2024
Study Completion
July 30, 2024
Last Updated
May 30, 2024
Record last verified: 2024-05